Sector
PharmaceuticalsOpen
₹795.95Prev. Close
₹795.9Turnover(Lac.)
₹71.29Day's High
₹812Day's Low
₹79052 Week's High
₹1,05452 Week's Low
₹650Book Value
₹258.49Face Value
₹10Mkt Cap (₹ Cr.)
374.34P/E
21.56EPS
36.92Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 12.86 | 4.64 | 3.99 | 3.99 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 83.52 | 63.42 | 39.08 | 37.33 |
Net Worth | 96.38 | 68.06 | 43.07 | 41.32 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 133.89 | 112.77 | 58.06 | 56.69 |
yoy growth (%) | 18.72 | 94.2 | 2.41 | 33.96 |
Raw materials | -101.77 | -80.14 | -39.51 | -37.17 |
As % of sales | 76 | 71.06 | 68.04 | 65.57 |
Employee costs | -8.65 | -8.94 | -5.18 | -4.91 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 4.37 | 2.49 | 2.64 | 2.22 |
Depreciation | -2 | -1.87 | -1.28 | -1.13 |
Tax paid | -1.19 | -0.59 | -0.89 | -0.79 |
Working capital | 7.41 | 38.35 | 2.4 | 0.25 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 18.72 | 94.2 | 2.41 | 33.96 |
Op profit growth | 10.51 | 95.94 | 27.02 | -14.89 |
EBIT growth | 23.5 | 50.86 | 11.66 | 3.5 |
Net profit growth | 5.92 | 8.62 | 22.66 | 33.46 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,776.15 | 150.91 | 4,20,027.58 | 237.82 | 0.77 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,855.95 | 78.49 | 1,30,370.29 | 430 | 0.61 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,575 | 32.24 | 1,28,058.81 | 1,055.94 | 0.82 | 3,752.25 | 346.4 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,178.65 | 27.87 | 1,21,729.16 | 1,700.8 | 0.25 | 4,035.4 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,953.2 | 28.24 | 1,16,346.95 | 1,417.2 | 0.57 | 5,823.9 | 1,458.7 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
WTD & Joint Managing Director
Daulat N Medhora
Executive Director
Nariman B Medhora
Non-Exec. & Independent Dir.
Aspi N Raimalwala
Managing Director & CFO
Fredun N Medhora
Non-Exec. & Independent Dir.
Rohinton Kanga
Company Sec. & Compli. Officer
Jinkal Shah
Additional Director
Daisy Dsouza
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Fredun Pharmaceuticals Ltd
Summary
Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals (FPL) was converted into a public limited company in Mar.94. The Company was promoted by Nariman Medhora and Daulat N Medhora. The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharmas operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems.The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind.In Apr.96, the company came out with a public issue to register its products in the overseas market for exports; to p
Read More
The Fredun Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹796.6 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Fredun Pharmaceuticals Ltd is ₹374.34 Cr. as of 23 Aug ‘24
The PE and PB ratios of Fredun Pharmaceuticals Ltd is 21.56 and 3.08 as of 23 Aug ‘24
The 52-week high/low is the highest and lowest price at which a Fredun Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Fredun Pharmaceuticals Ltd is ₹650 and ₹1054 as of 23 Aug ‘24
Fredun Pharmaceuticals Ltd's CAGR for 5 Years at 28.20%, 3 Years at 28.44%, 1 Year at -17.18%, 6 Month at -9.48%, 3 Month at -5.94% and 1 Month at -3.42%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.